SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that ...

The firm increased its portfolio allocation in ANAB by 55.02% over the last quarter. Frazier Life Sciences Management holds 2,209K shares representing 7.26% ownership of the company. In its prior ...